Get the Stockscreener App
0.00
100.00%
-2.27
Acelyrin Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Acelyrin Inc is a late-stage clinical biopharmaceutical company. The clinical biopharma segment researches and develops treatments for diseases with pathology related to excess activation of the immune system. It is focused on providing patients with life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines.
See More
Previous Close:
$2.27
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$227.15M
Revenue:
-
Net Income/Loss:
$-299.80M
P/E Ratio:
0.00
EPS:
-2.84
Net Cash Flow:
$-217.49M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$7.25
Acelyrin Inc Stock (SLRN) Company Profile
Name
Acelyrin Inc
Sector
Industry
Phone
805-456-4393
Address
4149 LIBERTY CANYON RD., AGOURA HILLS
Compare SLRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLRN
Acelyrin Inc
|
0.00 | 227.15M | 0 | -299.80M | -217.49M | -2.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.87 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
509.72 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
309.70 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.15 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
247.08 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Acelyrin Inc Stock (SLRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-08-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-08-23 | Initiated | Citigroup | Neutral |
| Sep-13-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-05-23 | Initiated | H.C. Wainwright | Buy |
| May-30-23 | Initiated | Jefferies | Buy |
| May-30-23 | Initiated | Morgan Stanley | Overweight |
| May-30-23 | Initiated | Piper Sandler | Overweight |
| May-30-23 | Initiated | TD Cowen | Outperform |
View All
Acelyrin Inc Stock (SLRN) Latest News
Acelyrin Requests to Dismiss Class Action Filed by Investors - TradingView
Guggenheim raises Alumis stock to buy with $18 price target By Investing.com - Investing.com Canada
Morgan Stanley Resumes Coverage of Alumis (ALMS) with $23 PT - MSN
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Acelyrin, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2024SLRN - ACCESS Newswire
Alumis resumed with a Buy at Guggenheim - TipRanks
Guggenheim raises Alumis stock to buy with $18 price target - Investing.com
Jane Street Group LLC Lowers Stock Holdings in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin, Inc. (NASDAQ:SLRN) Shares Bought by Bank of America Corp DE - Defense World
Acelyrin, Inc. (NASDAQ:SLRN) Shares Sold by Two Sigma Advisers LP - Defense World
Wellington Management Group LLP Invests $567,000 in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
INVESTOR ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 16, 2024 in Acelyrin LawsuitSLRN - ACCESS Newswire
ProShare Advisors LLC Purchases 5,617 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin, Inc. (NASDAQ:SLRN) Shares Bought by Deutsche Bank AG - Defense World
Acelyrin, Inc. (NASDAQ:SLRN) Shares Sold by Ameriprise Financial Inc. - Defense World
Alumis resumed with an Overweight at Morgan Stanley - TipRanks
BNP Paribas Financial Markets Invests $236,000 in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Northern Trust Corp Grows Position in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin, Inc.(NasdaqGS: SLRN) dropped from S&P TMI Index - marketscreener.com
Acelyrin, Inc.(NasdaqGS: SLRN) dropped from S&P Global BMI Index - marketscreener.com
Alumis completes merger with ACELYRIN, extends cash runway By Investing.com - Investing.com Canada
Alumis completes merger with ACELYRIN, extends cash runway - Investing.com Australia
Alumis Completes Merger With ACELYRIN, Strengthens Pipeline And Cash Runway - Nasdaq
Alumis, Acelyrin Close Merger - marketscreener.com
Alumis Inc. Completes Merger with ACELYRIN, Inc. - TipRanks
ACELYRIN Completes Merger and Delists from Nasdaq - TipRanks
Alumis Inc. Completes Merger with ACELYRIN, Inc. to Strengthen Pipeline in Immune-Mediated Disease Therapies - Nasdaq
Alumis completes merger with Acelyrin - TipRanks
Alumis Completes Merger with ACELYRIN - TradingView
Alumis-ACELYRIN Merger Creates Powerhouse in Immune Disease Drug Development with 2027 Cash Runway - Stock Titan
ACELYRIN Stockholders Approve Merger with Alumis - TipRanks
Alumis Inc. Stockholders Approve Merger with ACELYRIN - TipRanks
Dimensional Fund Advisors LP Buys New Shares in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements - The Manila Times
Alumis Inc. Reports First Quarter 2025 Financial Results - TradingView
How a Peninsula biotech's merger drama overcame several investor headaches - The Business Journals
ACELYRIN shareholders approve Alumis merger deal By Investing.com - Investing.com India
Alumis wins shareholder nod for ACELYRIN merger By Investing.com - Investing.com India
Alumis, Acelyrin Shareholders Approve Merger Deal - marketscreener.com
Alumis Stockholders Approve Merger with ACELYRIN - The Manila Times
Alumis wins shareholder nod for ACELYRIN merger - Investing.com
ACELYRIN shareholders approve Alumis merger deal - Investing.com
Alumis Inc. Stockholders Approve Merger with ACELYRIN, INC. - Nasdaq
Alumis Stockholders Approve Merger With Acelyrin - marketscreener.com
Acelyrin (SLRN) Stockholders Approve Merger with Alumis (ALMS) - StreetInsider
Alumis-ACELYRIN Merger Gets Green Light: Major Breakthrough for Immune Disease Treatment Pipeline - Stock Titan
Hsbc Holdings PLC Makes New $36,000 Investment in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin (SLRN) Projected to Post Earnings on Tuesday - Defense World
Barclays PLC Increases Stock Position in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Wells Fargo & Company MN Grows Holdings in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
INVESTOR ALERT: Potential Recovery for Acelyrin, Inc. (SLRN) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Acelyrin Inc Stock (SLRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.86%
1.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):